New Market Report: Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022
GlobalData has released its new PharmaPoint Drug Evaluation report, “Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
View full press release